Ethyl-EPA Treatment of Prodromal Patients

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00634361

Enrollment

Registered

2008-03-13

Start date

2001-09-30

Completion date

2005-08-31

Last updated

2014-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Prodrome

Brief summary

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Interventions

DRUGethyl-eicosapentaenoic acid

2 mg per day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

14 Years to 35 Years

Healthy volunteers

Inclusion criteria

* meets criteria for schizophrenia prodrome

Exclusion criteria

* any lifetime antipsychotic treatment

Design outcomes

Primary

Measure	Time frame
conversion to psychosis	one year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026